|Mr. Mark J. Foley||Pres, CEO & Director||59.5k||N/A||1965|
|Mr. Tobin C. Schilke||CFO & Principal Accounting Officer||89.88k||N/A||1975|
|Dr. Abhay Joshi||Chief Operating Officer||710.46k||19.21k||1963|
|Ms. Caryn Gordon McDowell||Sr. VP, Gen. Counsel & Corp. Sec.||537.47k||N/A||1970|
|Ms. Jeanie D. Herbert||Sr. Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
Revance Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine. It is also developing DAXI for forehead lines and lateral canthal lines; DaxibotulinumtoxinA Topical for therapeutic and aesthetic applications; and OnabotulinumtoxinA, a biosimilar to BOTOX. Revance Therapeutics, Inc. has a collaboration agreement with Mylan Ireland Limited for the development, manufacture, and commercialization of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.
Revance Therapeutics, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 8. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 8.